Stock THTX THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Theratechnologies Inc. Nasdaq

Equities

THTX

CA88338H7040

Market Closed - Nasdaq
Other stock markets
 21:30:00 17/07/2024 BST 		5-day change 1st Jan Change
1.535 USD -2.69% Intraday chart for Theratechnologies Inc. +2.33% -5.25%
07-10 Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 CI
07-10 Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 298.57 times its estimated earnings per share for the ongoing year.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
THERATECHNOLOGIES INC. Stock Theratechnologies Inc.
-5.25% 70.21M -
CSL LIMITED Stock CSL Limited
+8.54% 100B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+11.97% 43.89B
A-
BIOGEN INC. Stock Biogen Inc.
-11.76% 33.24B
B-
UCB Stock UCB
+80.35% 29.36B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-12.20% 16.08B
C
INCYTE CORPORATION Stock Incyte Corporation
+4.00% 14.68B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-1.90% 12.87B
D+
ALTEOGEN INC. Stock ALTEOGEN Inc.
+178.17% 10.55B
D
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+2.32% 8.83B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TH Stock
  4. THTX Stock
  5. Ratings Theratechnologies Inc.